Results 181 to 190 of about 54,010 (241)

Markers of immune activation and immunotherapy responsiveness are increased in 3D Pancreatic cancer organoids when primed with photodynamic- and chemo-therapy. [PDF]

Transl Oncol
Cabral FV, Quilez-Alburquerque J, Szoo MJ, de Silva P, Saad MA, Hasan T.   +5 more
europepmc   +1 more source

[Corrigendum] Influence of MLH1 on colon cancer sensitivity to poly(ADP‑ribose) polymerase inhibitor combined with irinotecan. [PDF]

Int J Oncol
Tentori L, Leonetti C, Muzi A, Dorio AS, Porru M, Dolci S, Campolo F, Vernole P, Lacal PM, Praz F, Graziani G.   +10 more
europepmc   +1 more source

Genotyping of DPYD and UGT1A1 in Brazilian oncological patients: applying pharmacogenomics in an admixed population. [PDF]

Rev Assoc Med Bras (1992)
Cereser VHB, Moniz CMV, Suarez-Kurtz G, Estevez-Diz MDP.   +3 more
europepmc   +1 more source

Prognostic significance of KRAS G12C versus non-G12C RAS mutations in metastatic colorectal cancer: a systematic review and meta-analysis. [PDF]

Oncologist
Khamis MM, Lapari MS, Alkharabsheh O, Baral MR, Sahin IH, Archwamety A, Firwana B, Patel GK, Singh A, Al Diffalha S, Manne U, Khushman M.   +11 more
europepmc   +1 more source

Klebsiella pneumoniae LPS drives stromal-mediated repression of p53 and colorectal cancer chemoresistance. [PDF]

Cell Death Dis
Fragkoulis K, Łasut-Szyszka B, Végvári Á, Ayona D, Saei AA, Aschtgen MS, Peuget S.   +6 more
europepmc   +1 more source

Clinical practice review of systemic treatment in large cell neuroendocrine carcinoma. [PDF]

Transl Lung Cancer Res
Cass AS, Luckage IC, Linden AG, Ramirez RA.   +3 more
europepmc   +1 more source

Butyrate prevents chemotherapy-induced gastrointestinal toxicity and microbial dysbiosis. [PDF]

Sci Rep
Cheatham SM, Rehman Z, Arastonejad M, Kane R, Ahmad N, Luffman N, Harada H, Zhang Y, Tyc KM, Gewirtz DA, Akbarali HI.   +10 more
europepmc   +1 more source

A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy. [PDF]

Support Care Cancer
Harikul W, Nimmannit A, Laocharoenkeat A, Phisalprapa P, Kositamongkol C, Thongkijpreecha P, Ithimakin S.   +6 more
europepmc   +1 more source

Pre-Therapeutic UGT1A1 Genotyping in Breast Cancer Patients Receiving Sacituzumab Govitecan to Improve Safety: A Meta-Analysis and Recommendation. [PDF]

Clin Transl Sci
Goedhart T, Guchelaar HJ.
europepmc   +1 more source

Sarcomas in Adolescents and Young Adults. [PDF]

Curr Oncol Rep
Greenmyer JR, Allen-Rhoades W.
europepmc   +1 more source